Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cefepime versus ceftriaxone plus aminoglycoside for chemotherapy-induced febrile neutropenia in children
IRCT20151205025372N3Phase 3Completed
- Sponsor
- Urmia University of Medical Sciences
- Start
- Oct 2021
- Modality
- Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label trial of cefepime, ceftriaxone, gentamicin and amikacin in febrile neutropenia (FN) (2 arms), sponsored by Urmia University of Medical Sciences. Primary endpoints: Mean duration of ICU stay, Mean duration of hospital stay and 3 more. Started Oct 2021; status: completed.
02
Drugs
cefepimeceftriaxonegentamicinamikacin
03
Conditions
febrile neutropenia (FN)
Beyond the preview
Go deeper on IRCT20151205025372N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20151205025372N3.